SciLifeLab is now launching a new Drug Discovery and Development platform. This national resource will offer drug discovery expertise to Swedish researchers in order to advance academic discoveries towards novel treatments of benefit to patients.

 

With support from the Swedish government, presented in the Research and Innovation Bill 2013-2016, SciLifeLab can now offer drug discovery expertise to Swedish researchers. This effort will combine academic groundbreaking discoveries with drug discovery expertise and development traditionally only found in the pharmaceutical industry.

“We believe that this will facilitate translation of existing innovative projects at Swedish universities towards therapeutic development”, says Karin Forsberg Nilsson, Scientific Director at SciLifeLab, and Acting Director for the Uppsala site of the DDD platform.

The Drug Discovery & Development platform (DDD platform) will focus on early drug discovery and take promising candidates as far as demonstrating in vivo efficacy in relevant models. Through an open call for projects, Swedish academic scientists will be able to propose projects for development at the platform. When a project have reached a level of maturity and commercial value it will have a small-molecule or human antibody lead and a documented line-of-sight for further development. The project can then be taken over by a multitude of potential stakeholders.

On October 2nd, the SciLifeLab board decided to make the following eight facilities available on a national level:

  • Recombinant protein expression and therapeutics
  • Biochemical and cellular screening
  • Human antibody therapeutics
  • Hit-to-lead
  • Lead identification chemistry
  • Molecular interactions & Structural biology
  • Uppsala Drug Optimization and Pharmaceutical Profiling (UDOPP)
  • In vitro & Systems pharmacology

The DDD platform has expertise in a wide range of areas and welcomes both small molecules and protein therapeutics projects.

“We have already started up parts of the operation, and are now looking to recruit scientists with drug discovery and development expertise to our eight facilities”, says Per Arvidsson, Platform Director for the Stockholm site of the DDD platform.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Ok!Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.